xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

342

KUANetal.

TABLE XXXI.A.1 Evidence surrounding morbidity related to extended maxillary approaches.

Clinical endpoints

Study

Year LOE Study design Study groups

Conclusion

SNOT-22

1. Lower preoperative SNOT-22 scores in benign tumors 2. Reduction in SNOT-22 scores at all time intervals in both benign and malignant tumors 3. Rhinologic, sleep, and psychological domains had greatest impact on QOL in benign tumors 4. Benign and malignant tumors had similar trend in 1. Baseline rhinologic and sleep domains have largest impact 2. Significant reduction in SNOT-20 at 6 months postoperatively (1.04 > 0.53) 3. Overall and all subdomains significantly lower in benign compared to malignant at 6months 1. Only postoperative data 2. Benign tumors had significantly 1. Lower preoperative SNOT-20 scores in benign tumors 2. Baseline rhinologic and sleep domains have largest impact 3. Significant reduction in mean SNOT-20 postoperatively in benign (1.11 > 0.58) 4. Insignificant reduction in SNOT-20 postoperatively in malignant tumors 1. QOL after prelacrimal approach to maxillary sinus 2. Preop SNOT-22 and VAS were better in the papilloma group, but only the nonpapilloma group demonstrated significant improvement postoperatively 3. No difference in postoperative VAS or SNOT-22 between papilloma and nonpapilloma groups (Continues) improvement, but malignant had higher scores at all time points improved ASBQ and SNOT-20 scores as compared to malignant tumors

Glicksman et al. 2093

2018 3

Prospective cohort

1. Benign tumors ( n = 81) 2. Malignant tumors ( n = 64)

Derousseau et al. 2090

2015 3

Prospective cohort

1. IP ( n = 32) 2. Malignant tumors ( n = 72)

SNOT-20

Deckard

2015 3

Prospective cohort

1. Benign ( n = 39) 2. Malignant ( n = 32)

1. SNOT-20 2. ASBQ 3. EQ-5D

et al. 2085

Harrowand Batra 2089

2013 3

Prospective cohort

1. Benign ( n = 45) 2. Malignant ( n = 49)

SNOT-20

Linand

1. SNOT-22 2. VAS for

2020 4

Retrospective case series

1. Papilloma ( n = 9) 2. Nonpapilloma ( n = 12)

Chen 2094

overall health